Skip to content
Screener

McKesson MCK Oncology & Multispecialty — Restructuring Reserve, Settled without Cash

Other segment segments

Prescription Technology Solutions
$40M
North American Pharmaceutical
$1M
Medical-Surgical Solutions
$0

Similar metrics at other companies

Playstudios logo
MYPSplayAWARDS — Restructuring Reserve, Settled without Cash
$71K
Playstudios logo
MYPSplayGAMES — Restructuring Reserve, Settled without Cash
$312K
Brunswick logo
BCBoat — Restructuring Reserve, Settled without Cash
$275K+467%
Brunswick logo
BCCorporate — Restructuring Reserve, Settled without Cash
$0
Brunswick logo
BCPropulsion — Restructuring Reserve, Settled without Cash
$0
Brunswick logo
BCNavico Group — Restructuring Reserve, Settled without Cash
$81.48M+256%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringReserveSettledWithoutCash2.

The source filing: McKesson’s 10-K, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal year
FY2026
Accession
0000927653-26-000069
(In millions)North American PharmaceuticalOncology & MultispecialtyPrescription Technology SolutionsMedical-Surgical SolutionsCorporate & OtherTotal
Balance, March 31, 2024 (1)$23$3$5$1$23$55
Restructuring, impairment, and related charges, net5911220468344
Non-cash charges(58)(1)(9)(14)(16)(98)
Cash payments(8)(2)(4)(99)(51)(164)
Other (2)(5)(1)(3)(2)(11)
Balance, March 31, 2025 (3)1119024126
Restructuring, impairment, and related charges, net242043158245
Non-cash charges(12)(17)8(8)(29)

Item 8. Financial Statements and Supplementary Data.

FAQ

What is McKesson's oncology & multispecialty — restructuring reserve, settled without cash?
McKesson (MCK) reported oncology & multispecialty — restructuring reserve, settled without cash of $0 in Q1 2026.
How has McKesson's oncology & multispecialty — restructuring reserve, settled without cash changed year-over-year?
McKesson's oncology & multispecialty — restructuring reserve, settled without cash decreased by 100.0% year-over-year, from $250K to $0.
What does oncology & multispecialty — restructuring reserve, settled without cash mean?
Restructuring obligations that were satisfied through non-cash means, such as the issuance of equity, asset write-downs, or other non-monetary settlements. This highlights the impact of restructuring on the balance sheet without immediate cash outflow.

Ask your AI about McKesson's oncology & multispecialty — restructuring reserve, settled without cash.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude